Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.

East MP, Olivares-Quintero JF, Okumu DO, Mott KR, Sprung RW, Whitman AA, Joisa CU, Chen X, Zhang Q, Erdmann-Gilmore P, Mi Y, Malone JP, Bhatia S, McCabe IC, Xu Y, Sutcliffe MD, Spears PA, Zawistowski JS, Perou CM, Earp HS, Carey LA, Yeh JJ, Spector DL, Stover D, Gomez SM, Spanheimer PM, Townsend RR, Johnson GL

Open source

DOI: 10.64898/2026.09.16.752096
Published: 2026 Sep 18
Container: bioRxiv : the preprint server for biology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.64898/2026.09.16.752096,
  title = {Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.},
  author = {East MP and Olivares-Quintero JF and Okumu DO and Mott KR and Sprung RW and Whitman AA and Joisa CU and Chen X and Zhang Q and Erdmann-Gilmore P and Mi Y and Malone JP and Bhatia S and McCabe IC and Xu Y and Sutcliffe MD and Spears PA and Zawistowski JS and Perou CM and Earp HS and Carey LA and Yeh JJ and Spector DL and Stover D and Gomez SM and Spanheimer PM and Townsend RR and Johnson GL},
  year = {2026},
  journal = {bioRxiv : the preprint server for biology},
  doi = {10.64898/2026.09.16.752096},
  url = {https://doi.org/10.64898/2026.09.16.752096}
}

RIS

TY  - JOUR
TI  - Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.
AU  - East MP
AU  - Olivares-Quintero JF
AU  - Okumu DO
AU  - Mott KR
AU  - Sprung RW
AU  - Whitman AA
AU  - Joisa CU
AU  - Chen X
AU  - Zhang Q
AU  - Erdmann-Gilmore P
AU  - Mi Y
AU  - Malone JP
AU  - Bhatia S
AU  - McCabe IC
AU  - Xu Y
AU  - Sutcliffe MD
AU  - Spears PA
AU  - Zawistowski JS
AU  - Perou CM
AU  - Earp HS
AU  - Carey LA
AU  - Yeh JJ
AU  - Spector DL
AU  - Stover D
AU  - Gomez SM
AU  - Spanheimer PM
AU  - Townsend RR
AU  - Johnson GL
PY  - 2026
JO  - bioRxiv : the preprint server for biology
DO  - 10.64898/2026.09.16.752096
UR  - https://doi.org/10.64898/2026.09.16.752096
ER  -

APA

MP, E., JF, O., DO, O., KR, M., RW, S., AA, W., CU, J., X, C., Q, Z., P, E., Y, M., JP, M., S, B., IC, M., Y, X., MD, S., PA, S., JS, Z., CM, P., HS, E., LA, C., JJ, Y., DL, S., D, S., SM, G., PM, S., RR, T., & GL, J. (2026). Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.. bioRxiv : the preprint server for biology. https://doi.org/10.64898/2026.09.16.752096

Source records

pubmed · retrieved 2026-09-25T04:39:49.221Z